Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer

Seung Yoon Yang; Jae Hyun Kang; Ho Seung Kim; Yoon Dae Han; Byung Soh Min; Kang Young Lee

doi:10.21037/jgo.2019.01.36

Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer

J Gastrointest Oncol. 2019 Dec;10(6):1251-1265. doi: 10.21037/jgo.2019.01.36.

Authors

Seung Yoon Yang¹, Jae Hyun Kang¹, Ho Seung Kim¹, Yoon Dae Han¹, Byung Soh Min¹, Kang Young Lee¹

Affiliation

¹ Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.

Abstract

Peritoneal carcinomatosis (PC) was previously considered an incurable disease with a poor survival outcome. As our understanding of its biology evolved, the paradigm of the management of PC from colorectal cancer (CRC) has changed, including the combination of macroscopic disease control, cytoreductive surgery (CRS), maximal regional chemotherapy to treat residual microscopic disease, and hyperthermic intraperitoneal chemotherapy (HIPEC). As with many surgical innovations, CRS with HIPEC has evolved faster than data to support it, leaving many skeptics and critics. This review highlights the recent evidence of current practice and outcome of CRS with HIPEC. Furthermore, it also summarizes the ongoing clinical trials and potential future progress of this treatment modality.

Keywords: Colorectal cancer (CRC); cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal carcinomatosis (PC).

Publication types

Review